Young Seok Cho

Young Seok Cho

Auto-generated profile, based on publicly available information

Young Seok Cho

Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2024 in Nature Materials
Verified
Journal Article
Closed access
PDF file
KHKai Han
Kai Han
FXFang Xie
Fang Xie
OAOlamide Animasahun
Olamide Animasahun
MNMinal Nenwani
Minal Nenwani
SKSho Kitamoto
Sho Kitamoto
JMJames Moon
James Moon

27 March 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
YJYeonwoo Jang
Yeonwoo Jang
YCYoung Seok Cho
Young Seok Cho
AKApril Kim
April Kim
XZXingwu Zhou
Xingwu Zhou
YKYujin Kim
Yujin Kim
HPHansoo Park
Hansoo Park

1 October 2021 in Biomaterials
Verified
Journal Article
Open access
NLNa Kyeong Lee
Na Kyeong Lee
JCJeong Uk Choi
Jeong Uk Choi
HKHa Rin Kim
Ha Rin Kim
SCSeung Woo Chung
Seung Woo Chung
YKYoon Gun Ko
Yoon Gun Ko
YBYoungro Byun
Youngro Byun
Here we report a novel combination of a caspase-cleavable peptide-doxorubicin conjugate (MPD-1) with CD47-antagonizing nanocage therapeutics for the treatment of microsatellite-stable (MSS) colorectal cancer (CRC). MPD-1 (i) upregulated markers of immunogenic cell death (ICD) in tumor, and increased co-stimulatory markers on dendritic cells (DCs), (ii) enhanced CD8+ T cell infiltration and antigen presenting cell (APC) activation, and (iii) showed negligible off-target immune-related toxicity compared to free dox. Then, the CD47 antagonist FS nanocage, a SIRPα-expressing ferritin nanocage, was co-administered with MPD-1 that resulted in 95.2% (p < 0.001) tumor growth inhibition in an established CRC model. T cell-mediated elimination of tumors was also confirmed by the tumor-specific activation of T cells detected by IFNγ and tumor-free mice were observed (95%) that bared a memory response when re-challenged. The strategically developed MPD-1 is an ideal adjuvant to immunotherapy and the combination with FS nanocage triggers potent immunity against MSS CRC. In summary, we present an approach to initiate and stimulate immune-mediated eradication of cancer cells using synergistic immunogenic agents targeting the MSS CRC.

25 May 2024 in Biomaterials
Verified
Journal Article
Closed access
SPSeong Jin Park
Seong Jin Park
SKSeho Kweon
Seho Kweon
MMMudhibadhi Knowledge Moyo
Mudhibadhi Knowledge Moyo
HKHa Rin Kim
Ha Rin Kim
JCJeong Uk Choi
Jeong Uk Choi
YBYoungro Byun
Youngro Byun

7 May 2026 in Science
Verified
Journal Article
Closed access
XZXingwu Zhou
Xingwu Zhou
XLXiang Ling
Xiang Ling
XSXiaoqi Sun
Xiaoqi Sun
ZWZiye Wan
Ziye Wan
TDTobias Dwyer
Tobias Dwyer
JMJames Moon
James Moon
Natural systems use metal ions to form ordered structures that regulate biological processes, inspiring the rational design of nanotherapeutics. The cyclic guanosine monophosphate–adenosine monophosphate synthase–stimulator of interferon genes (cGAS-STING) pathway drives antitumor immunity but has been difficult to activate systemically owing to poor pharmacology and toxicity. Here, we report CRYSTAL, a structurally ordered intermetallic nanoparticle for potent systemic STING activation. CRYSTAL self-assembles from manganese ions intercalated with cyclic dinucleotides, enabling precise structural control. At an ultralow intravenous dose (0.003 milligrams per kilogram), CRYSTAL activated STING in mice, dogs, and nonhuman primates without cytokine release syndrome. CRYSTAL induced robust tumor regression in advanced murine and rabbit models, remodeled immunosuppressive environments, and promoted host STING–dependent CD8 + T cell priming. CRYSTAL activated interferon responses in human head and neck squamous cell carcinoma biopsies, underscoring its translational potential for cancer immunotherapy.

3 November 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YCYoung Seok Cho
Young Seok Cho
XZXingwu Zhou
Xingwu Zhou
XSXiaoqi Sun
Xiaoqi Sun
ZWZiye Wan
Ziye Wan
JCJulia Crowther
Julia Crowther
JMJames Moon
James Moon
Toll-like receptor (TLR) agonists, as potent immunostimulatory adjuvants, play a critical role in linking the innate and adaptive immune responses. However, their antitumor effects as cancer immunotherapeutic agents have been limited. Here, we report our finding that manganese ion (Mn 2+ ) potentiates various TLR agonists, leading to robust activation of the TLR pathway and the stimulator of interferon genes (STING) pathway among innate immune cells. In particular, we have observed robust antitumor efficacy after intratumoral administration of a TLR3 agonist and Mn 2+ . To achieve systemic codelivery of TLR3 agonist and Mn 2+ , we have developed a low-molecular-weight poly(inosinic:cytidylic acid)-Mn 2+ coordination lipid nanoparticle (PLCMP). When administered intravenously in tumor-bearing mice, PLCMP successfully accumulated in tumor, induced innate immune activation, generated tumor-specific T cells, and exerted antitumor efficacy in TLR3- and STING-dependent manner without triggering overt toxicity. Moreover, PLCMP in combination with α-PD-1 therapy achieved long-lasting antitumor efficacy in multiple murine tumor models. Furthermore, vaccination with PLCMP carrying TC-1 tumor antigen peptide elicited strong antigen-specific CD8 + T cell responses and remodeled the tumor microenvironment, resulting in robust therapeutic efficacy. Overall, these results show that simultaneous activation of the TLR3 and STING pathways via PLCMP provides a promising strategy for immunotherapy and vaccination against cancer.